World Journal of Urology最新文献

{"title":"Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy","authors":"Anjali L. Saripalli, Bhanu Prasad Venkatesulu, Nicholas G. Nickols, Luca F. Valle, Matthew M. Harkenrider, Amar U. Kishan, Abhishek A. Solanki","doi":"10.1007/s00345-024-05205-9","DOIUrl":"https://doi.org/10.1007/s00345-024-05205-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Intraprostatic recurrence (IRR) of prostate cancer after radiation therapy is increasingly identified. Our objective was to review the literature to determine the optimal workup for identifying IRR, the management options, and practical considerations for the delivery of re-irradiation as salvage local therapy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We performed a systematic review of available publications and ongoing studies on the topics of IRR, with a focus on salvage re-irradiation.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Work up of biochemically recurrent prostate cancer includes PSMA PET/CT and multiparametric MRI, followed by biopsy to confirm IRR. Management options include continued surveillance, palliative hormonal therapy, and salvage local therapy. Salvage local therapy can be delivered using re-irradiation with low dose rate brachytherapy, high dose rate (HDR) brachytherapy, and stereotactic body radiotherapy (SBRT), as well as non-radiation modalities, such as cryotherapy, high-intensity focused ultrasound, irreversible electroporation and radical prostatectomy. Data demonstrate that HDR brachytherapy and SBRT have similar efficacy compared to the other salvage local therapy modalities, while having more favorable side effect profiles. Recommendations for radiation therapy planning and delivery using HDR and SBRT based on the available literature are discussed.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Salvage re-irradiation is safe and effective and should be considered in patients with IRR.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered","authors":"Pierre-Etienne Gabriel, Géraldine Pignot, Michael Baboudjian, Cédric Lebacle, Alexandre Chamouni, Eric Lechevallier, Jacques Irani, Xavier Tillou, Thibaut Waeckel, Arnaud Monges, Jochen Walz, Gwenaelle Gravis, Céline Duperron, Xavier Carpentier, Clément Klein, Alexandra Masson-Lecomte","doi":"10.1007/s00345-024-05219-3","DOIUrl":"https://doi.org/10.1007/s00345-024-05219-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To report the oncological outcomes and the tolerance between 6 instillations and more than 6 cycles of hyperthermic intravesical chemotherapy(HIVEC) in patients with non-muscle invasive bladder cancer(NMIBC).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This is a multicenter retrospective study from a national database including 9 expert centers. All patients treated with HIVEC between 2016 and 2023 for NMIBC were included. Patients were classified into two groups according to the total number of HIVEC instillations, including induction plus maintenance. Kaplan-Meier curves were computed to present survival outcomes.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>261 patients with a median follow-up of 25.5 months were included. 199(76.2%) and 62(23.8%) were treated by 6 and more than 6 cycles of HIVEC, respectively. The 2-years RFS(40.2% vs. 34.4%,<i>p</i> = 0.3) and the 2-years PFS(86% vs. 87%,<i>p</i> = 0.85) were similar between group treated with 6 and more than 6 instillations. 2-years CSS and OS were also similar between both groups. Univariate Cox regression showed no association between the number of bladder instillation and RFS (HR = 1.2 95%CI[0.8–1.84], <i>p</i> = 0.3) or PFS (HR = 0.8 95%CI[0.29–2.02], <i>p</i> = 0.2). In the group treated with more than 6 cycles, 2-years RFS and 2-years PFS were similar between patients who received induction plus maintenance compared to those treated with induction only. Finally, hematuria and urinary burning were significantly higher in the group treated by more than 6 cycles (21% vs. 8.5%(<i>p</i> &lt; 0.01),and 29% vs. 17% (<i>p</i> = 0.03), respectively). Serious side effects(grade ≥ 3) are rare(3.1%) and similar in both groups.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Results show no significant difference in two years RFS, PFS, CSS and OS according to number of instillations received, while toxicity profile seems better in the group receiving six instillations only.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and feasibility of “three arms settings” robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case series","authors":"Alberto Ragusa, Francesco Prata, Andrea Iannuzzi, Francesco Tedesco, Loris Cacciatore, Alessandro Rocca, Paolo Caccia, Catalina Bogea, Monica Marelli, Angelo Civitella, Roberto Mario Scarpa, Giovanni Muto, Rocco Papalia","doi":"10.1007/s00345-024-05210-y","DOIUrl":"https://doi.org/10.1007/s00345-024-05210-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Robot-assisted laparoscopic radical prostatectomy (RARP) is the most common robotic procedures performed in urologic oncology. The Hugo Robot-Assisted Surgery (RAS) System (Medtronic, USA©) has recently been launched on the market and is characterized by the modularity of four different independent arm carts. The aim of this study is to describe and evaluate safety and feasibility of three-arms setting for RARP using the Hugo RAS™ System in a large case series.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Between October 2022 and December 2023, a large case series of patients from two tertiary referral center who underwent RARP through HUGO™ RAS were prospectively enrolled. Informed written consent was obtained before the procedure and a three-arms setting was used in every case. Follow-up was scheduled according to EAU guidelines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 86 patients were included in this study and underwent RARP with Hugo™ RAS System. Median Console time time was 114 min (IQR, 75–150), median docking time 4 min (IQR, 3–5). Lymphadenectomy was successfully performed when indicated in 19 patients (22.1%). A vesicourethral anastomosis using the modified Van Velthoven technique was successfully achieved in all cases. No post-operative complications &gt; Clavien II up to 30 post-operative days were reported. In all patients, catheter was removed on the 7th postoperative day.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>We conducted the first large case series of RARP through the novel Hugo™ RAS System using a three-arms configuration. This innovative robotic platform showed an easily accessible docking system, providing excellent perioperative outcomes.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year outcomes of polyacrylamide hydrogel (Bulkamid) injection in women with stress and mixed urinary incontinence","authors":"Alessandro Uleri, Fabienne Marchand, Arnaud Cherasse, William Berchiche, Christopher Agüero, Mamadou B. Bah, Michael Baboudjian, Marc Fourmarier","doi":"10.1007/s00345-024-05221-9","DOIUrl":"https://doi.org/10.1007/s00345-024-05221-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aimed to evaluate the efficacy and safety following treatment with Bulkamid for stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We retrospectively analyzed data of women diagnosed with SUI or stress-predominant MUI who underwent Bulkamid periurethral injection between November 2020 and January 2023 and completed 12 months of follow-up. The primary outcome of the study was to assess patient satisfaction, which was measured on a four-point scale, ranging from cured to worse, and through validated questionaries such as the International Consultation on Incontinence Questionnaire-short Form (ICIQ-UI SF) and Contilife Quality of Life questionnaire.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 70 patients included, 41 (59%) had MUI with predominant stress incontinence. Median age was 59 years (IQR 47–75), with a median BMI of 25 (18–40) and a median number of pregnancies of 2 (0–4). Forty-seven (67%) procedures were performed under sedation and 23 (33%) under local anesthesia. Forty-three (69%) women reported feeling cured or improved at 12 months follow-up and among them, 25 (40%) reported feeling cured. A total of 16 (23%) patients were subsequently treated, in detail 11 (16%) patients underwent MUS positioning, and 5 (7%) had an additional injection of Bulkamid. ICIQ and Contilife QoL showed a significant improvement at 1, 3, 6, and 12 months (all <i>p</i> &lt; 0.001).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Bulkamid injections are an effective and safe treatment option for women with SUI or stress-predominant MUI, providing good outcomes at 12 months.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer","authors":"Juan Gomez Rivas, Mark Taratkin, Camilla Azilgareeva, Andrey Morozov, Silvia Laso, Dmitry Enikeev, Jesús Moreno Sierra, Ksenia Schelkunova, Francesco Sanguedolce, Alberto Breda, Alexander Govorov, Alexander Vasilyev, Marcos Cepeda, Lukas Lusuardi, Maximilian Pallauf, Antonio Celia, Tommaso Silvestri, Cristian Fiori, Esaú Fernández, Juan Ignacio Martínez-Salamanca, Eric Barret","doi":"10.1007/s00345-024-05199-4","DOIUrl":"https://doi.org/10.1007/s00345-024-05199-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>The aim of this study is to compare outcomes of SRP (salvage radical prostatectomy) with SCAP (salvage cryoablation of the prostate) in local radio-recurrent PCa (prostate cancer) patients.</p><h3 data-test=\"abstract-sub-heading\">Materials and methods</h3><p>A retrospective analysis of a multicentric European Society of Uro-technology (ESUT) database was performed. Data on patients with local recurrent PCa after radiotherapy who underwent salvage treatment were collected. Patients and their respective disease characteristics, perioperative complications as well as oncological outcomes were then described. The treatment success rate was defined as PSA nadir &lt; 0,4 ng/ml. Any complications were graded according to the modified Clavien system. A descriptive and comparative analysis was performed using SPSS software.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>25 patients underwent SRP and 71 patients received SCAP. The mean follow-up was 24 months. The median PSA level before initial treatment was 8.3 (range 7-127) ng/ml. The success rates of SRP and SCAP were largely comparable (88% (22 patients) vs. 67.7% (48 patients), respectively, <i>p</i> = 0.216). The mean serum PSA levels at 12 months after salvage treatment were 1.2 ± 0.2 ng/mL vs. 0.25 ± 0.5 ng/mL, <i>p</i> &gt; 0.05). During the follow-up period, only 3 (12%) patients in the SRP group had PSA recurrence compared with 21 patients (29.6%) in the SCAP group. The 5-year BRFS was similar (51,6% and 48,2%, <i>p</i> = 0,08) for SRP and SCAP respectively. The 5-year overall survival rate was 91.7%, and 89,7% (<i>p</i> = 0.669) and the 5-year cancer-specific survival was 91.7%, and 97,1% (<i>p</i> = 0.077), after SRP and SCAP respectively. No difference was found regarding the complications.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Both SRP and SCAP should be considered as valid treatment options for patients with local recurrence of PCa after radiotherapy. SCAP has a potentially lower risk of morbidity and acceptable intermediate-term oncological efficacy, but a longer follow up and a higher number of patients is ideally needed to draw any long-term conclusions regarding the oncological data.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nocturia and obstructive sleep apnea in spinal cord injured patients – a cohort study","authors":"C. Lambert, J. Di Maria, P. Denys, A. Even, A. Welniarz, S. Hartley, H. Prigent, A. Leotard, Charles Joussain","doi":"10.1007/s00345-024-05190-z","DOIUrl":"https://doi.org/10.1007/s00345-024-05190-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To describe the prevalence of nocturia and obstructive sleep apnea (OSA) in a cohort of spinal cord injury (SCI) patients and to describe their association. Additionally, to assess clinical and urodynamic data explaining nocturia and to evaluate the effect of OSA management with continuous positive airway pressure (CPAP).</p><h3 data-test=\"abstract-sub-heading\">Method</h3><p>Retrospective analysis of data from patients with SCI followed in a tertiary care rehabilitation center with a specialized sleep and neuro-urology units. All adult SCI patients who underwent urodynamic assessment before polysomnography (PSG) between 2015 and 2023 were eligible. Subjective (nocturia) and objective data (urodynamic data, polysomnography, CPAP built-in software) were collated from the Handisom database (database register no. 20200224113128) and the medical records of SCI patients. Statistical testing used Mann-Whitney test for non-parametric variables, Fisher’s exact test for contingency analysis and the Spearman correlation test to assess correlations. A p-value &lt; 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism v9.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>173 patients (131 males, 42 females) were included. The majority of patients were paraplegic (<i>n</i> = 111 (64,2%)) and had complete lesions (<i>n</i> = 75 (43,4%)). A total of 100 patients had nocturia (57,5%). The prevalence of OSA (Apnea Hypopnea Index (AHI) ≥ 15/h) in the studied population was 61,9%. No correlation was found between nocturia and OSA. A significant difference was observed between patients with and without nocturia in terms of the presence of neurogenic detrusor overactivity (<i>p</i> = 0,049), volume at the first detrusor contraction (<i>p</i> = 0,004) and the bladder functional capacity (<i>p</i> &lt; 0,001).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Nocturia and OSA are highly prevalent in patients with SCI, but no statistical association was found between these two disorders. A prospective study focusing on nocturnal polyuria will be needed to assess the impact of OSA on lower urinary tract symptoms in SCI patients.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture combined with extracorporeal shock wave lithotripsy is beneficial for the expulsion of ureteral calculi: a prospective randomized trial.","authors":"Heng Zhang, Lihua Li, Weizheng Li, Wei Wei, Tianyu Bai, Qiang Wei, Yongliang Ni","doi":"10.1007/s00345-024-05226-4","DOIUrl":"https://doi.org/10.1007/s00345-024-05226-4","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the therapeutic efficacy and safety of electroacupuncture (EA) combined with extracorporeal shock wave lithotripsy (ESWL) in treating ureteral calculi.</p><p><strong>Methods: </strong>This prospective randomized controlled trial included 207 patients with ureteral calculi who were randomly allocated to an experimental group that underwent EA plus ESWL (n = 95) and a control group that underwent only ESWL (n = 112). Imaging examinations were performed at 1, 2, and 4 weeks after the operation, followed by comparing the stone-clearance rate, time to first stone expulsion, and incidence of major complications between the two groups.</p><p><strong>Results: </strong>The stone-clearance rates at 1 (59.1 vs. 37%, P = 0.002), 2 (86.4 vs. 59.3%, P = 0.000), and 4 (90.9 vs. 77.8%, P = 0.013) weeks after the operation in the experimental group were significantly higher than those in the control group. The time to first stone expulsion in the experimental group was significantly lower than that in the control group (1.29 ± 1.55 vs. 2.45 ± 3.11 days, respectively; P = 0.001). However, we found no difference in the incidence of major complications between the two groups (15.9 vs. 17.6%, P = 0.754).</p><p><strong>Conclusion: </strong>EA-assisted ESWL significantly improved stone clearance and shortened the time to stone expulsion without elevating the complication risk. However, a large-scale multicenter, prospective study is required to corroborate our conclusions.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor about \"Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis\".","authors":"Yi Qiang, Yuquan Chen, Jiatong Pan, Qiang Cao","doi":"10.1007/s00345-024-05224-6","DOIUrl":"https://doi.org/10.1007/s00345-024-05224-6","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort","authors":"Jauffray Oliva, Vassili Anastay, Michael Baboudjian, Mathieu Roumiguié, Alexandre Peltier, Charles Dariane, Gaelle Fiard, Thierry Roumeguère, Romain Diamand, Mohamed Bakhri, Jean-Baptiste Beauval, Thibaut Long-Depaquit, Guillaume Ploussard, Alessandro Uleri","doi":"10.1007/s00345-024-05227-3","DOIUrl":"https://doi.org/10.1007/s00345-024-05227-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>To investigate whether initial tumor burden at biopsy could predict adverse features after radical prostatectomy (RP) in International Society of Urological Pathology (ISUP) 1 prostate cancer (PCa) patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This retrospective study was conducted in six referral centers. The cohort included patients with ISUP 1 PCa at systematic and MRI-targeted biopsy. We defined a high tumor burden at biopsy if ≥ 20% of cores were positive. The endpoint of the study was adverse features at RP, defined as ≥ pT3a stage and/or N1 and/or ISUP ≥ 3. Sensitivity analyses were performed to assess associations between different thresholds on biopsy (percentage of positive cores [PPC] ≥ 25%, ≥ 33%, ≥ 50%, bilateral positivity and positive cores &gt; 3) and adverse features. As the number of targeted biopsies sampled may influence the number of positive cores, we used a virtual biopsy model in which all targeted biopsy results were interpreted as a single targeted biopsy.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 312 contemporary patients were included. At final pathology, 99 patients (32%) had adverse features. In multivariate logistic regression analysis, there was no statistical association between PPC &gt; 20% and adverse features (OR = 1.22; 95%CI:0.69–2.22, <i>p</i> = 0.5). In sensitivity analysis, tumor burden at biopsy was not associated with the risk of adverse features, regardless of the definition used (all <i>p</i> &gt; 0.05). When we considered a unique virtual targeted biopsy, tumor burden remained not associated with adverse features (all <i>p</i> &gt; 0.05).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>ISUP 1 PCa tumor burden at biopsy did not predict adverse features in this study, suggesting that it should not be used alone as an exclusion criterion when assessing eligibility for active surveillance.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to letter to the editor for the article \"Risk factors of early infectious complications after ureterorenoscopy for stone disease: a prospective study\".","authors":"Vincent De Coninck, Brecht Devos, Etienne Xavier Keller","doi":"10.1007/s00345-024-05211-x","DOIUrl":"https://doi.org/10.1007/s00345-024-05211-x","url":null,"abstract":"","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}